WO2012035904A1 - Agent for promoting hyaluronic acid production - Google Patents
Agent for promoting hyaluronic acid production Download PDFInfo
- Publication number
- WO2012035904A1 WO2012035904A1 PCT/JP2011/067829 JP2011067829W WO2012035904A1 WO 2012035904 A1 WO2012035904 A1 WO 2012035904A1 JP 2011067829 W JP2011067829 W JP 2011067829W WO 2012035904 A1 WO2012035904 A1 WO 2012035904A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- acid production
- skin
- present
- plant
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 78
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 76
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 76
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 56
- 230000001737 promoting effect Effects 0.000 title abstract description 20
- 239000003795 chemical substances by application Substances 0.000 title abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims description 19
- 241000196324 Embryophyta Species 0.000 abstract description 24
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 10
- 230000032683 aging Effects 0.000 abstract description 9
- 206010003246 arthritis Diseases 0.000 abstract description 5
- 244000052909 Dioscorea esculenta Species 0.000 abstract description 3
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract description 3
- 230000037394 skin elasticity Effects 0.000 abstract description 2
- 206010042496 Sunburn Diseases 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000037393 skin firmness Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 26
- 239000000203 mixture Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 235000013305 food Nutrition 0.000 description 14
- 239000002537 cosmetic Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 240000005979 Hordeum vulgare Species 0.000 description 6
- 235000007340 Hordeum vulgare Nutrition 0.000 description 6
- 229940069780 barley extract Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- -1 diosgenin glycoside Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 244000281702 Dioscorea villosa Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 235000004879 dioscorea Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- 108091022885 ADAM Proteins 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 235000005903 Dioscorea Nutrition 0.000 description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000025255 bacterial arthritis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940023308 vitamin b6 20 mg Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/032—Citric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/064—Proline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2116—Flavonoids, isoflavones
- A23V2250/21172—Soy Isoflavones, daidzein, genistein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
- A23V2250/284—Oligosaccharides, non digestible
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A23V2250/314—Ubiquinone, coenzyme Qn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
- A23V2250/51082—Carboxymethyl cellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5114—Dextrins, maltodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5422—Collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/6402—Erythritol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7044—Vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7052—Vitamin B6
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/712—Vitamin E
Definitions
- the present invention relates to a hyaluronic acid production promoter having a hyaluronic acid production promoting action.
- hyaluronic acid retains moisture in the cell gap, retains cells based on the formation of a jelly-like matrix in the tissue, retains the lubricity and flexibility of the tissue, and resists external forces such as mechanical failure. And has many functions such as prevention of bacterial infection (see Non-Patent Document 1).
- Non-Patent Document 1 it is said that the amount of hyaluronic acid in the skin decreases with aging, and along with this, skin aging such as fine lines and roughness appears.
- many cosmetics containing hyaluronic acid and collagen have been proposed as an ameliorating agent for such aging skin.
- these conventional cosmetics only exhibit a moisturizing effect on the skin surface, and cannot essentially improve aging skin.
- cosmetics containing various vitamins and herbal medicines as skin cell activators have been proposed, but these have not yet been able to improve and treat aging skin.
- the hyaluronic acid contained in the joint fluid covers the surface of the articular cartilage and is useful for smooth operation of the joint function.
- Hyaluronic acid concentration in normal human joint fluid is about 2.3 mg / ml, but in the case of rheumatoid arthritis, hyaluronic acid concentration in joint fluid is reduced to about 1.2 mg / ml and at the same time the viscosity of joint fluid is Remarkably reduced (see Non-Patent Document 2).
- hyaluronic acid content decreases in pyogenic arthritis and gouty arthritis as in the case of rheumatoid arthritis (see Non-Patent Document 3).
- hyaluronic acid is known to increase markedly in the granulation during the period from the beginning of the granulation tissue growing from below the necrotic tissue until the entire tissue is replaced with the granulation tissue. (See Non-Patent Document 6), hyaluronic acid production promoters are also expected as an early treatment for burns.
- the present inventors have conducted extensive research, and as a result, found that the specific plant or extract thereof has an excellent hyaluronic acid production promoting action and is useful as a hyaluronic acid production promoter, The present invention has been completed.
- the present invention provides a hyaluronic acid production promoter comprising a plant of Tedokoro or an extract thereof.
- the plant body may be a dry powder of a plant of Tedokoro.
- the plant body may be a tuber of a plant of Tedokoro.
- the present invention provides a method for preventing aging of human skin, holding a beam, holding elasticity, and / or improving moisture retention, including the step of applying the hyaluronic acid production promoter.
- the applying step may be oral administration.
- the hyaluronic acid production promoter of the present invention has an excellent hyaluronic acid production promoting action, preventing human skin aging, especially prevention and treatment of arthritis, etc., including skin agglomeration and elasticity retention, initial treatment of burns It can be effectively applied to the above.
- ingredients derived from natural products are used, it is safe to take for humans or animals.
- the hyaluronic acid production promoter of the present invention has an excellent hyaluronic acid production promoting ability. Therefore, the hyaluronic acid production promoter of the present invention is suitable as a material for pharmaceuticals (for example, external preparations for skin and internal medicine), quasi drugs, and cosmetics. Moreover, it is applicable also to food-drinks (for example, a supplement and a drink).
- Tedokoro (scientific name: Dioscorea esculenta) used in the present invention is a plant of the genus Dioscorea.
- Tedokoro is a kind of yam that is cultivated and edible mainly in the south of Kyushu, is said to have nourishing tonic action, and is known to contain diosgenin and its glycoside (Japanese Patent Application Laid-Open No. 2007-274985). ). Further, it has an ADAM (a disintegrin and metalloprotease) inhibitory action and is used as an anti-wrinkle agent (Japanese Patent Application Laid-Open No. 2008-94734), and a plant belonging to the genus Dioscorea prevents loss of skin elasticity and wrinkles (Special Table 2004) -515523) is known.
- ADAM disintegrin and metalloprotease
- the spine that is used in the present invention may be derived from any part, and is not particularly limited. For example, stalks, roots, stalks, leaves, or a mixture thereof can be used, and particularly preferably, stalks are used. can do.
- stalks, roots, stalks, leaves, or a mixture thereof can be used, and particularly preferably, stalks are used. can do.
- the toggedokoro there are no particular limitations on the toggedokoro, and commercially available products can be used. Examples of the commercially available products include “Tedokoro Powder” (manufactured by Takara Bio Inc.), which is a dried powder of Togedokoro.
- the plant body is not particularly limited, but for example, there is no particular limitation as long as the raw material Tedokoro is subjected to some processing, for example, ground product, dry powder, extract, pulverized product, juice , Crushed material, chemically treated material, enzyme-treated material, particularly preferably ground material and dry powder.
- the ground product refers to a product obtained by grinding down a tuber of Tedokoro, and is usually prepared by using various automatic grinders or by manually grinding it.
- examples of the dry powder include a pulverized product derived from Tedokoro used in the present invention (hereinafter sometimes referred to as the pulverized product of the present invention).
- examples of the method for producing a pulverized product of the present invention include a method of obtaining a powdered pulverized product obtained by drying powdered tubers and pulverizing them using a pulverizer. Further, a pulverized product may be obtained by freeze pulverization or pulverization after freeze-drying.
- Extract refers to the substance itself obtained through a process of performing extraction operation on a raw material plant using an extraction solvent.
- the extraction can be performed as follows by a known extraction method. For example, after pulverizing or chopping the raw material, it can be carried out batchwise or continuously using a solvent.
- the extraction solvent for obtaining the extract is not particularly limited, but water, chloroform, ethanol, methanol, isopropyl alcohol and other alcohols, acetone, methyl ethyl ketone and other ketones, methyl acetate, ethyl acetate and other hydrophilic or An oleophilic solvent can be used, and it can be used alone or as a mixture as appropriate.
- An example of using the mixed solution as an extraction solvent is not particularly limited, but various aqueous solutions can be used, for example, 10 to 95%, preferably 15 to 90%, more preferably 20 to 85% alcohol.
- An aqueous solution can be used.
- the amount of the extraction solvent may be appropriately determined.
- the raw material plant is used in the form of the raw material plant as it is (for example, a raw plant if the raw plant is a raw plant), preferably 2 to A 100-fold amount of extraction solvent may be used.
- the extraction temperature may be appropriately determined according to the purpose, but in the case of water extraction, it is usually preferably 4 to 130 ° C, more preferably 25 to 100 ° C. When ethanol is contained in the solvent, a temperature range of 4 to 60 ° C.
- the extraction time may be determined in consideration of the extraction efficiency.
- the raw material, the extraction solvent, and the extraction temperature are set so as to be preferably in the range of several seconds to several days, more preferably 5 minutes to 24 hours. Is preferred.
- the extraction operation may be performed, for example, while stirring or standing, and may be repeated several times as necessary.
- a spiny extract can be obtained. If necessary, the extract can be subjected to a treatment such as filtration, centrifugation, concentration, ultrafiltration, molecular sieving, etc. to prepare an extract in which the diosgenin glycoside is concentrated. It is also possible to use two or more types of extracts obtained by different extraction methods from raw material plants.
- the hyaluronic acid production promoter of the present invention is preferably composed of a Tedokoro plant or an extract thereof, but can contain other various components as long as the effects of the present invention are not impaired.
- the hyaluronic acid production promoter of the present invention can be used in humans and animals by blending it with an external preparation for skin, and it can be blended with various foods and drinks, feeds (such as pet food) and ingested. It can also be administered to humans and animals as a pharmaceutical formulation. At this time, it may be adjusted by arbitrarily drying, concentrating or diluting depending on the dosage form and form of the external preparation for skin and food and drink.
- the blending amount (dry mass) is preferably about 0.0001 to 10% by mass in the total amount of the external preparation.
- components that are usually used in external preparations for skin such as cosmetics and pharmaceuticals within the range that does not impair the effects of the present invention, if necessary, such as antioxidants Oils, UV protection agents, surfactants, thickeners, alcohols, powder components, color materials, aqueous components, water, various skin nutrients, and the like can be appropriately blended as necessary.
- gluconic acid preservatives such as methylparaben, ethylparaben, butylparaben, caffeine, tannin, Verapamil,
- the external preparation for skin can be applied to cosmetics, quasi-drugs, etc., particularly preferably cosmetics applied to the outer skin, and the dosage form can also be applied to the skin.
- Any dosage form such as solution system, solubilization system, emulsification system, powder dispersion system, water-oil two-layer system, water-oil-powder three-layer system, ointment, lotion, gel, aerosol, etc. is applicable. Is done.
- the form of use is also arbitrary, and for example, it can be used for facial cosmetics such as lotions, emulsions, creams and packs, makeup cosmetics such as foundations, lipsticks and eye shadows, aromatic cosmetics, bath preparations and the like.
- makeup cosmetics can be widely applied to foundations and other toiletry products such as body soaps and soaps. Furthermore, if it is a quasi-drug, it can be widely applied to various ointment forms. And the form which can take the hyaluronic acid production promoter of this invention is not limited to these dosage forms and forms.
- the blending amount (dry mass) of the plant body or its extract is appropriately determined according to the type, purpose, form, usage method, etc. For example, 1 to 90% by mass is preferable for tablets and capsules in the total amount of food and drink, and 0.001 to 50% by mass for other foods and drinks. It is preferable to prepare so that the daily intake of the plant or its extract per adult is about 1 to 1,000 mg. In particular, when used as a health food or drink, it is preferable to contain the active ingredient of the present invention in such an amount that a predetermined effect is sufficiently exhibited.
- the form of food and drink or feed for example, it can be arbitrarily shaped into granules, granules, pastes, gels, solids, or liquids.
- These include various known substances that are recognized to be contained in foods and drinks, such as binders, disintegrants, thickeners, dispersants, reabsorption accelerators, flavoring agents, buffers, and surfactants. Excipients such as solubilizers, preservatives, emulsifiers, tonicity agents, stabilizers and pH adjusters may be included as appropriate.
- the preparation is appropriately used orally or parenterally (intravenous administration, intraperitoneal administration, etc.).
- the dosage form is also arbitrary, for example, oral solid preparations such as tablets, granules, powders and capsules, oral liquid preparations such as internal liquids and syrups, and parenteral liquid preparations such as injections. These forms can also be appropriately prepared by known methods.
- binders for these pharmaceutical preparations, commonly used binders, disintegrants, thickeners, dispersants, reabsorption accelerators, corrigents, buffers, surfactants, solubilizers, preservatives, emulsifiers, isotonicity Excipients such as agents, stabilizers and pH adjusters may be used as appropriate.
- the hyaluronic acid production promoter of the present invention When used as an external preparation for skin, foods and drinks, pharmaceutical preparations, etc., it has excellent hyaluronic acid production promoting action to prevent aging of human skin, retention of skin tension and elasticity, prevention of arthritis -Effectively used for treatment and early treatment of burns. When added to a food, it is expected that the hyaluronic acid production promoting effect will be exhibited from the inside by ingesting the food.
- the method for adding the hyaluronic acid production promoter of the present invention to an external preparation for skin or food and drink may be added in advance or during production, and may be appropriately selected in consideration of workability. It ’s fine.
- Hyaluronic acid production promoting effect test method The hyaluronic acid production promoting action of the sample obtained above was evaluated. That is, when a human epidermal keratinocyte is seeded in a 24-well plate at a concentration of 5.0 ⁇ 10 4 cells / well and brought into a confluent state, each sample group (final concentration 1 ⁇ g / mL, 10 ⁇ g / mL) is included. 500 ⁇ L of EpiLife-KG2 culture medium was added. After the addition, after 72 hours of incubation, the amount of hyaluronic acid produced was measured by ELISA. A DMSO / PBS solution (no sample added) was used as a control example (control).
- Hyaluronan assay kit manufactured by Seikagaku Biobusiness
- the unit of the measured value is hyaluronan (synonymous with hyaluronic acid) production (ng / mL).
- the plant of the present invention has an excellent hyaluronic acid production promoting effect, and is useful as a hyaluronic acid production promoter. Therefore, by incorporating the hyaluronic acid production promoter of the present invention, it is possible to provide an external preparation for skin having an effect of promoting hyaluronic acid production, an oral composition (for example, a functional agent, food and drink), a pharmaceutical preparation and the like. It is useful for prevention, prevention, improvement, treatment, etc. of various symptoms, diseases, and pathological conditions. Specific examples of application include prevention, improvement and treatment of skin aging such as sagging / wrinkling of skin, reduction of elasticity and elasticity, prevention / treatment of arthritis, and early treatment of burns. However, application is not limited to these examples.
- formulation examples of hyaluronic acid production promoters according to the present invention in various dosage forms will be described as formulation examples. Needless to say, the present invention is not limited by these formulation examples and is specified by the scope of claims.
- “Tagedokoro powder” manufactured by Takara Bio Inc. was used as the hyaluronic acid production promoter.
- Hyaluronic acid production promoter Tedokoro powder (dry mass) 140mg Collagen peptide 70mg Pearl barley extract (dry mass) 20mg Lotus germ extract (dry mass) 40mg Vitamin C 150mg Soy isoflavone 270mg Reduced lactose 360mg Soybean oligosaccharide 36mg Erythritol 36mg Dextrin 30mg Fragrance 24mg Citric acid 24mg (Total) 1200mg
- Hyaluronic acid production promoter Tedokoro powder (dry mass) 100mg Collagen peptide 5mg Pearl barley extract (dry mass) 2mg Reduced maltose starch syrup 28mg Erythritol 8mg Citric acid 2mg Fragrance 1.3mg N-acetylglucosamine 1mg Hyaluronic acid 0.5mg Vitamin E 0.3mg ⁇ -Lipoic acid 0.2mg Coenzyme Q10 1.2mg Ceramide (konjac extract) 0.4mg L-proline 2mg Water residue
Abstract
Provided is an agent for promoting hyaluronic acid production that has excellent hyaluronic acid production-promoting capability and is effective in the prevention of aging of human skin, particularly in the maintenance of skin firmness and elasticity, and in the prevention and treatment of arthritis etc., and also in the early treatment etc. of sunburn. The agent for promoting hyaluronic acid production provided by the present invention comprises Dioscorea esculenta or an extract thereof. The Dioscorea esculenta is used in the form of a dried power or tuber of the plant in the agent for promoting hyaluronic acid production of the present invention.
Description
本発明はヒアルロン酸産生促進作用を有するヒアルロン酸産生促進剤に関するものである。
The present invention relates to a hyaluronic acid production promoter having a hyaluronic acid production promoting action.
近年、老化に関する研究が進められている。皮膚老化の原因は、マクロ的にみれば加齢が重要な因子であるが、それに加えて乾燥、酸化、太陽光（紫外線）等による影響も皮膚老化に関わる直接的な因子として挙げられる。皮膚老化の具体的な現象としては、ヒアルロン酸をはじめとするムコ多糖類の減少、コラーゲンの架橋反応、紫外線による細胞の損傷などが知られている。
In recent years, research on aging has been underway. As for the cause of skin aging, aging is an important factor when viewed macroscopically, but in addition to that, the effects of drying, oxidation, sunlight (ultraviolet rays) and the like are also directly related to skin aging. As specific phenomena of skin aging, reduction of mucopolysaccharides such as hyaluronic acid, cross-linking reaction of collagen, cell damage due to ultraviolet rays, and the like are known.
なかでもヒアルロン酸は、細胞間隙への水分の保持、組織内にジェリー状のマトリックスを形成することに基づく細胞の保持、組織の潤滑性と柔軟性の保持、機械的障害等の外力に対する抵抗、および細菌感染の防止など、多くの機能を有している（非特許文献１参照）。例えば、皮膚のヒアルロン酸量は加齢とともに減少し、それに伴い、小じわやかさつき等の皮膚老化が現れるといわれている。そのため、このような老化した皮膚の改善剤として、ヒアルロン酸やコラーゲンを配合した化粧料が数多く提案されている。しかしながらこれら従来の化粧料は、皮膚表面における保湿効果を発揮するだけであり、本質的に老化肌を改善し得るものではない。また、皮膚細胞賦活剤として各種のビタミン類や生薬類を配合した化粧料が提案されているが、これらもやはり老化肌を改善、治療し得るまでには至っていないのが現状である。
Among them, hyaluronic acid retains moisture in the cell gap, retains cells based on the formation of a jelly-like matrix in the tissue, retains the lubricity and flexibility of the tissue, and resists external forces such as mechanical failure. And has many functions such as prevention of bacterial infection (see Non-Patent Document 1). For example, it is said that the amount of hyaluronic acid in the skin decreases with aging, and along with this, skin aging such as fine lines and roughness appears. For this reason, many cosmetics containing hyaluronic acid and collagen have been proposed as an ameliorating agent for such aging skin. However, these conventional cosmetics only exhibit a moisturizing effect on the skin surface, and cannot essentially improve aging skin. In addition, cosmetics containing various vitamins and herbal medicines as skin cell activators have been proposed, but these have not yet been able to improve and treat aging skin.
さらに、関節液中に含まれるヒアルロン酸は、関節軟骨の表面を覆い、関節機能の円滑な作動に役立っている。正常人関節液中のヒアルロン酸濃度は約２．３ｍｇ／ｍｌであるが、慢性関節リウマチの場合、関節液中のヒアルロン酸濃度は約１．２ｍｇ／ｍｌと低下し、同時に関節液の粘度も著しく低下する（非特許文献２参照）。また、化膿性関節炎や痛風性関節炎などでも慢性関節リウマチの場合と同様、ヒアルロン酸含量の低下が起こることが知られている（非特許文献３参照）。上記疾患において、潤滑機能の改善、関節軟骨の被覆・保護、疼痛抑制および病的関節液の改善若しくは正常化のために、関節液中のヒアルロン酸量を増加させることが考えられる。例えば、慢性関節リウマチ患者にヒアルロン酸ナトリウムの関節注入療法を行うと上記の改善が認められることが報告されている（非特許文献４参照）。同様に、外傷性関節炎、骨関節炎や変形性関節炎においても、ヒアルロン酸の関節注入療法により上記の改善効果が報告されている。（非特許文献５参照）。
Furthermore, the hyaluronic acid contained in the joint fluid covers the surface of the articular cartilage and is useful for smooth operation of the joint function. Hyaluronic acid concentration in normal human joint fluid is about 2.3 mg / ml, but in the case of rheumatoid arthritis, hyaluronic acid concentration in joint fluid is reduced to about 1.2 mg / ml and at the same time the viscosity of joint fluid is Remarkably reduced (see Non-Patent Document 2). In addition, it is known that hyaluronic acid content decreases in pyogenic arthritis and gouty arthritis as in the case of rheumatoid arthritis (see Non-Patent Document 3). In the above diseases, it is conceivable to increase the amount of hyaluronic acid in synovial fluid in order to improve lubrication function, cover / protect articular cartilage, suppress pain, and improve or normalize pathological joint fluid. For example, it has been reported that the above-mentioned improvement is observed when sodium hyaluronate joint injection therapy is performed on patients with rheumatoid arthritis (see Non-Patent Document 4). Similarly, in traumatic arthritis, osteoarthritis and osteoarthritis, the above-mentioned improvement effect has been reported by joint injection therapy with hyaluronic acid. (Refer nonpatent literature 5).
このように、皮膚にはヒアルロン酸を配合した化粧料を塗布したり、また関節には直接ヒアルロン酸を注入するなどの方法がとられているが、ヒアルロン酸を外から与えても根本的機能改善にはならず、充分な効果は期待できない。特に、ヒアルロン酸は、皮膚からはほとんど吸収されないという問題がある。
In this way, cosmetics containing hyaluronic acid are applied to the skin, and hyaluronic acid is directly injected into the joint. However, even if hyaluronic acid is applied from the outside, the fundamental function is achieved. It is not an improvement and a sufficient effect cannot be expected. In particular, there is a problem that hyaluronic acid is hardly absorbed from the skin.
このため、単にヒアルロン酸そのものを外から補給するのではなく、本来ヒトが備え持っている生体の自己回復力を利用し、ヒトの皮膚線維芽細胞自身のヒアルロン酸産生能を促進させることによって、生体の機能を根本的に改善する物質の開発が期待されており、中でも、植物由来のヒアルロン酸産生促進剤が、その安全性や皮膚への刺激の穏やかさを期待して種々開発されている（例えば、特許文献１～３参照）。
For this reason, instead of simply replenishing hyaluronic acid itself from the outside, by utilizing the self-healing power of the living body inherently possessed by humans, by promoting the hyaluronic acid producing ability of human skin fibroblasts themselves, Development of substances that fundamentally improve the functions of living organisms is expected, and among them, various plant-derived hyaluronic acid production promoters have been developed with the expectation of safety and mildness of skin irritation. (For example, see Patent Documents 1 to 3).
また、熱傷受傷後の治癒過程で、壊死組織の下方から増生してくる肉芽組織の初期から組織全体が肉芽組織に置き換えられるまでの期間では、肉芽中にヒアルロン酸が著しく増加することが知られており（非特許文献６参照）、熱傷の初期の治療薬としても、ヒアルロン酸産生促進剤は期待されている。
In the healing process after burn injury, hyaluronic acid is known to increase markedly in the granulation during the period from the beginning of the granulation tissue growing from below the necrotic tissue until the entire tissue is replaced with the granulation tissue. (See Non-Patent Document 6), hyaluronic acid production promoters are also expected as an early treatment for burns.
このように、ヒアルロン酸産生促進作用を有するものとして従来より植物由来の抽出物が、その安全性や皮膚への刺激の穏やかさを期待して種々開発されているが、今までに該効果を奏することが見出されていなかった新しい植物で新たなヒアルロン酸産生促進効果を奏する植物のさらなる開発が求められている。
本発明はこのような従来の事情に対処してなされたもので、新しい植物由来のヒアルロン酸産生促進剤を提供することを目的とする。 As described above, various extracts derived from plants have been developed in the past as having hyaluronic acid production promoting action, expecting the safety and mildness of irritation to the skin. There is a need for further development of a new plant that has not been found to exhibit a new hyaluronic acid production promoting effect.
The present invention has been made in view of such conventional circumstances, and an object thereof is to provide a new plant-derived hyaluronic acid production promoter.
本発明はこのような従来の事情に対処してなされたもので、新しい植物由来のヒアルロン酸産生促進剤を提供することを目的とする。 As described above, various extracts derived from plants have been developed in the past as having hyaluronic acid production promoting action, expecting the safety and mildness of irritation to the skin. There is a need for further development of a new plant that has not been found to exhibit a new hyaluronic acid production promoting effect.
The present invention has been made in view of such conventional circumstances, and an object thereof is to provide a new plant-derived hyaluronic acid production promoter.
本発明者等は、このような現状に鑑み、鋭意研究を重ねた結果、特定の植物又はその抽出物に優れたヒアルロン酸産生促進作用がありヒアルロン酸産生促進剤として有用であることを見出し、本発明を完成するに至った。
In view of the current situation, the present inventors have conducted extensive research, and as a result, found that the specific plant or extract thereof has an excellent hyaluronic acid production promoting action and is useful as a hyaluronic acid production promoter, The present invention has been completed.
本発明は、トゲドコロの植物体又はその抽出物を含む、ヒアルロン酸産生促進剤を提供する。
DETAILED DESCRIPTION OF THE INVENTION The present invention provides a hyaluronic acid production promoter comprising a plant of Tedokoro or an extract thereof.
本発明のヒアルロン酸産生促進剤において、前記植物体はトゲドコロの植物体の乾燥粉末の場合がある。
In the hyaluronic acid production promoter of the present invention, the plant body may be a dry powder of a plant of Tedokoro.
本発明のヒアルロン酸産生促進剤において、前記植物体はトゲドコロの植物体の塊茎の場合がある。
In the hyaluronic acid production promoter of the present invention, the plant body may be a tuber of a plant of Tedokoro.
本発明は、前記ヒアルロン酸産生促進剤を適用するステップを含む、ヒト皮膚の老化の防止、はりの保持、弾力の保持、及び／又は、保湿性の改善を行う方法を提供する。前記適用するステップは、経口的な投与の場合がある。
The present invention provides a method for preventing aging of human skin, holding a beam, holding elasticity, and / or improving moisture retention, including the step of applying the hyaluronic acid production promoter. The applying step may be oral administration.
本発明のヒアルロン酸産生促進剤は優れたヒアルロン酸産生促進作用を有しており、ヒト皮膚の老化防止、特に皮膚のはりや弾力保持をはじめ、関節炎等の予防・治療、熱傷の初期の治療等に有効に適用され得る。また、天然物由来の成分を用いていることから、人又は動物に対して内服しても安全なものである。
The hyaluronic acid production promoter of the present invention has an excellent hyaluronic acid production promoting action, preventing human skin aging, especially prevention and treatment of arthritis, etc., including skin agglomeration and elasticity retention, initial treatment of burns It can be effectively applied to the above. In addition, since ingredients derived from natural products are used, it is safe to take for humans or animals.
以下、本発明について詳述する。
本発明のヒアルロン酸産生促進剤は、優れたヒアルロン酸産生促進能を有している。よって、本発明のヒアルロン酸産生促進剤は、医薬品（例えば皮膚外用剤，内服薬），医薬部外品，および化粧料の材料として好適である。また、飲食品（例えばサプリメント，飲料）にも適用することができる。 Hereinafter, the present invention will be described in detail.
The hyaluronic acid production promoter of the present invention has an excellent hyaluronic acid production promoting ability. Therefore, the hyaluronic acid production promoter of the present invention is suitable as a material for pharmaceuticals (for example, external preparations for skin and internal medicine), quasi drugs, and cosmetics. Moreover, it is applicable also to food-drinks (for example, a supplement and a drink).
本発明のヒアルロン酸産生促進剤は、優れたヒアルロン酸産生促進能を有している。よって、本発明のヒアルロン酸産生促進剤は、医薬品（例えば皮膚外用剤，内服薬），医薬部外品，および化粧料の材料として好適である。また、飲食品（例えばサプリメント，飲料）にも適用することができる。 Hereinafter, the present invention will be described in detail.
The hyaluronic acid production promoter of the present invention has an excellent hyaluronic acid production promoting ability. Therefore, the hyaluronic acid production promoter of the present invention is suitable as a material for pharmaceuticals (for example, external preparations for skin and internal medicine), quasi drugs, and cosmetics. Moreover, it is applicable also to food-drinks (for example, a supplement and a drink).
本発明で用いられるトゲドコロ（学名：Dioscorea esculenta）は、ヤマノイモ科ヤマノイモ属の植物である。
トゲドコロは主に九州以南で栽培され、食用されているヤムイモの一種であり、滋養強壮作用を有するとされ、ジオスゲニンやその配糖体を含むものであることが知られている（特開２００７－２７４９８５）。また、ＡＤＡＭ（a disintegrin and metalloprotease）阻害作用を有し、抗しわ剤として用いられること（特開２００８－９４７３４）、およびＤｉｏｓｃｏｒｅａ属植物が皮膚の弾性の喪失や小皺を防止すること（特表２００４－５１５５２３）が知られている。 Tedokoro (scientific name: Dioscorea esculenta) used in the present invention is a plant of the genus Dioscorea.
Tedokoro is a kind of yam that is cultivated and edible mainly in the south of Kyushu, is said to have nourishing tonic action, and is known to contain diosgenin and its glycoside (Japanese Patent Application Laid-Open No. 2007-274985). ). Further, it has an ADAM (a disintegrin and metalloprotease) inhibitory action and is used as an anti-wrinkle agent (Japanese Patent Application Laid-Open No. 2008-94734), and a plant belonging to the genus Dioscorea prevents loss of skin elasticity and wrinkles (Special Table 2004) -515523) is known.
トゲドコロは主に九州以南で栽培され、食用されているヤムイモの一種であり、滋養強壮作用を有するとされ、ジオスゲニンやその配糖体を含むものであることが知られている（特開２００７－２７４９８５）。また、ＡＤＡＭ（a disintegrin and metalloprotease）阻害作用を有し、抗しわ剤として用いられること（特開２００８－９４７３４）、およびＤｉｏｓｃｏｒｅａ属植物が皮膚の弾性の喪失や小皺を防止すること（特表２００４－５１５５２３）が知られている。 Tedokoro (scientific name: Dioscorea esculenta) used in the present invention is a plant of the genus Dioscorea.
Tedokoro is a kind of yam that is cultivated and edible mainly in the south of Kyushu, is said to have nourishing tonic action, and is known to contain diosgenin and its glycoside (Japanese Patent Application Laid-Open No. 2007-274985). ). Further, it has an ADAM (a disintegrin and metalloprotease) inhibitory action and is used as an anti-wrinkle agent (Japanese Patent Application Laid-Open No. 2008-94734), and a plant belonging to the genus Dioscorea prevents loss of skin elasticity and wrinkles (Special Table 2004) -515523) is known.
しかしながら、トゲドコロの植物体またはその抽出物にヒアルロン酸産生促進作用があるという報告はこれまでになく、本発明者らによって初めて見出されたものである。
However, there has never been a report that the plant body of Tedokoro or its extract has a hyaluronic acid production promoting action, and it has been found for the first time by the present inventors.
本発明で用いられるトゲドコロはいずれの部位由来でもよく、特に限定はないが、例えば茎塊、根、茎、葉、又はこれらの混合物を使用することができ、特に好適には、茎塊を使用することができる。トゲドコロは特に限定はなく市販のものを使用することができ、市販品としては例えばトゲドコロの乾燥粉末である「トゲドコロ粉末」（タカラバイオ社製）が挙げられる。
The spine that is used in the present invention may be derived from any part, and is not particularly limited. For example, stalks, roots, stalks, leaves, or a mixture thereof can be used, and particularly preferably, stalks are used. can do. There are no particular limitations on the toggedokoro, and commercially available products can be used. Examples of the commercially available products include “Tedokoro Powder” (manufactured by Takara Bio Inc.), which is a dried powder of Togedokoro.
本発明において、植物体とは特に限定はないが、例えば、原料のトゲドコロに対し何らかの加工を施したものであれば特に限定はなく、例えば磨砕物、乾燥粉末、抽出物、粉砕物、搾汁液、破砕物、化学処理物、酵素処理物をいい、特に好適には磨砕物、乾燥粉末が例示される。
In the present invention, the plant body is not particularly limited, but for example, there is no particular limitation as long as the raw material Tedokoro is subjected to some processing, for example, ground product, dry powder, extract, pulverized product, juice , Crushed material, chemically treated material, enzyme-treated material, particularly preferably ground material and dry powder.
本発明において磨砕物とは、トゲドコロの塊茎を摩り下ろしたもののことをいい、通常は種々の自動すり機を使用するか、もしくは手作業により摩り下ろして調製する。
In the present invention, the ground product refers to a product obtained by grinding down a tuber of Tedokoro, and is usually prepared by using various automatic grinders or by manually grinding it.
また、本発明において、乾燥粉末としては、例えば、本発明に使用されるトゲドコロ由来の粉砕物（以下、本発明の粉砕物と称することがある。）が例示される。本発明の粉砕物の製造方法としては、例えばトゲドコロの塊茎を乾燥させ、粉砕機を使用して粉砕することで粉状のトゲドコロ由来の粉砕物を得る方法が挙げられる。また、凍結粉砕や、凍結乾燥後粉砕することにより粉砕物を得てもよい。
In the present invention, examples of the dry powder include a pulverized product derived from Tedokoro used in the present invention (hereinafter sometimes referred to as the pulverized product of the present invention). Examples of the method for producing a pulverized product of the present invention include a method of obtaining a powdered pulverized product obtained by drying powdered tubers and pulverizing them using a pulverizer. Further, a pulverized product may be obtained by freeze pulverization or pulverization after freeze-drying.
抽出物とは原料植物に対し抽出溶媒を用いて抽出操作を行う工程を経て得られる物質そのもののことをいう。抽出は、公知の抽出方法により以下のように行うことができる。例えば原料を粉砕もしくは細断した後、溶媒を用いてバッチ式もしくは連続式で行うことができる。抽出物を得る際の抽出溶媒としては、特に限定はないが、水、クロロホルム、エタノール、メタノール、イソプロピルアルコール等のアルコール類、アセトン、メチルエチルケトン等のケトン類、酢酸メチル、酢酸エチル等の親水性もしくは親油性の溶媒を挙げることができ、所望により単独で、もしくは適宜混合液として用いることができる。混合液を抽出溶媒として用いる例としては、特に限定はないが、例えば各種水溶液を用いることができ、例えば１０～９５％、好適には１５～９０％、さらに好適には２０～８５％のアルコール水溶液を使用することができる。抽出溶媒の量は適宜決定すればよいが、通常、原料植物に対し、使用時の原料植物の形態そのまま（例えば原料植物が生の植物であれば生の植物）の重量の、好ましくは２～１００倍量の抽出溶媒を使用すれば良い。抽出温度も適宜、目的に応じて決定すれば良いが、水抽出の場合は通常、好ましくは４～１３０℃、より好ましくは２５～１００℃である。また、溶媒中にエタノールが含まれる場合は安全性の観点から４～６０℃の範囲が好適である。抽出時間も、抽出効率を考慮し決定すればよいが、通常、好ましくは数秒～数日間、より好ましくは５分～２４時間の範囲となるように、原料、抽出溶媒、抽出温度を設定するのが好適である。抽出操作は、たとえば、攪拌しながら又は静置して行えばよく、また、必要に応じて数回繰り返してもよい。
Extract refers to the substance itself obtained through a process of performing extraction operation on a raw material plant using an extraction solvent. The extraction can be performed as follows by a known extraction method. For example, after pulverizing or chopping the raw material, it can be carried out batchwise or continuously using a solvent. The extraction solvent for obtaining the extract is not particularly limited, but water, chloroform, ethanol, methanol, isopropyl alcohol and other alcohols, acetone, methyl ethyl ketone and other ketones, methyl acetate, ethyl acetate and other hydrophilic or An oleophilic solvent can be used, and it can be used alone or as a mixture as appropriate. An example of using the mixed solution as an extraction solvent is not particularly limited, but various aqueous solutions can be used, for example, 10 to 95%, preferably 15 to 90%, more preferably 20 to 85% alcohol. An aqueous solution can be used. The amount of the extraction solvent may be appropriately determined. Usually, the raw material plant is used in the form of the raw material plant as it is (for example, a raw plant if the raw plant is a raw plant), preferably 2 to A 100-fold amount of extraction solvent may be used. The extraction temperature may be appropriately determined according to the purpose, but in the case of water extraction, it is usually preferably 4 to 130 ° C, more preferably 25 to 100 ° C. When ethanol is contained in the solvent, a temperature range of 4 to 60 ° C. is preferable from the viewpoint of safety. The extraction time may be determined in consideration of the extraction efficiency. Usually, the raw material, the extraction solvent, and the extraction temperature are set so as to be preferably in the range of several seconds to several days, more preferably 5 minutes to 24 hours. Is preferred. The extraction operation may be performed, for example, while stirring or standing, and may be repeated several times as necessary.
以上の操作により、トゲドコロ抽出物を得ることができる。抽出物は必要に応じ、ろ過、遠心分離、濃縮、限外ろ過、分子ふるい等の処理を行うことで、ジオスゲニン配糖体が濃縮された抽出物を調製することができる。また、原料植物から異なった抽出法で得られた抽出物を２種以上含有させて使用することもできる。
By the above operation, a spiny extract can be obtained. If necessary, the extract can be subjected to a treatment such as filtration, centrifugation, concentration, ultrafiltration, molecular sieving, etc. to prepare an extract in which the diosgenin glycoside is concentrated. It is also possible to use two or more types of extracts obtained by different extraction methods from raw material plants.
本発明のヒアルロン酸産生促進剤はトゲドコロ植物体又はその抽出物からなるものであることが好ましいが、本発明の効果を損なわない範囲において他の種々の成分を含有することが出来る。
The hyaluronic acid production promoter of the present invention is preferably composed of a Tedokoro plant or an extract thereof, but can contain other various components as long as the effects of the present invention are not impaired.
本発明のヒアルロン酸産生促進剤は、皮膚外用剤に配合してヒトおよび動物に用いることができる他、各種飲食品、飼料（ペットフード等）に配合して摂取させることができる。また医薬製剤としてヒトおよび動物に投与することができる。この際、皮膚外用剤、飲食品などの剤型・形態により乾燥、濃縮又は希釈などを任意に行い調整すれば良い。
The hyaluronic acid production promoter of the present invention can be used in humans and animals by blending it with an external preparation for skin, and it can be blended with various foods and drinks, feeds (such as pet food) and ingested. It can also be administered to humans and animals as a pharmaceutical formulation. At this time, it may be adjusted by arbitrarily drying, concentrating or diluting depending on the dosage form and form of the external preparation for skin and food and drink.
本発明のヒアルロン酸産生促進剤を皮膚外用剤に配合する場合、その配合量（乾燥質量）は外用剤全量中、概ね０．０００１～１０質量％が好ましい。
When the hyaluronic acid production promoter of the present invention is blended with the external preparation for skin, the blending amount (dry mass) is preferably about 0.0001 to 10% by mass in the total amount of the external preparation.
本発明を皮膚外用剤に適用する場合、上記成分に加えて、さらに必要により、本発明の効果を損なわない範囲内で、通常化粧品や医薬品等の皮膚外用剤に用いられる成分、例えば酸化防止剤、油分、紫外線防御剤、界面活性剤、増粘剤、アルコール類、粉末成分、色材、水性成分、水、各種皮膚栄養剤等を必要に応じて適宜配合することができる。
When the present invention is applied to an external preparation for skin, in addition to the above components, components that are usually used in external preparations for skin such as cosmetics and pharmaceuticals within the range that does not impair the effects of the present invention, if necessary, such as antioxidants Oils, UV protection agents, surfactants, thickeners, alcohols, powder components, color materials, aqueous components, water, various skin nutrients, and the like can be appropriately blended as necessary.
さらに、エデト酸二ナトリウム、エデト酸三ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリウム、メタリン酸ナトリウム、グルコン酸等の金属イオン封鎖剤、メチルパラベン、エチルパラベン、ブチルパラベン等の防腐剤、カフェイン、タンニン、ベラパミル、トラネキサム酸およびその誘導体、甘草抽出物、グラブリジン、カリンの果実の熱水抽出物、各種生薬、酢酸トコフェロール、グリチルリチン酸およびその誘導体またはその塩等の薬剤、ビタミンＣ、アスコルビン酸リン酸マグネシウム、アスコルビン酸グルコシド、アルブチン、コウジ酸等の美白剤、グルコース、フルクトース、マンノース、ショ糖、トレハロース等の糖類なども適宜配合することができる。
Furthermore, edetate disodium, edetate trisodium, sodium citrate, sodium polyphosphate, sodium metaphosphate, sequestering agents such as gluconic acid, preservatives such as methylparaben, ethylparaben, butylparaben, caffeine, tannin, Verapamil, tranexamic acid and its derivatives, licorice extract, grabrizine, hot water extract of karin fruit, various herbal medicines, tocopherol acetate, glycyrrhizic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, Whitening agents such as ascorbic acid glucoside, arbutin, and kojic acid, and sugars such as glucose, fructose, mannose, sucrose, and trehalose can also be appropriately blended.
またこの皮膚外用剤は、外皮に適用される化粧料、医薬部外品等、特に好適には化粧料に広く適用することが可能であり、その剤型も、皮膚に適用できるものであればいずれでもよく、溶液系、可溶化系、乳化系、粉末分散系、水－油二層系、水－油－粉末三層系、軟膏、化粧水、ゲル、エアゾール等、任意の剤型が適用される。
The external preparation for skin can be applied to cosmetics, quasi-drugs, etc., particularly preferably cosmetics applied to the outer skin, and the dosage form can also be applied to the skin. Any dosage form such as solution system, solubilization system, emulsification system, powder dispersion system, water-oil two-layer system, water-oil-powder three-layer system, ointment, lotion, gel, aerosol, etc. is applicable. Is done.
使用形態も任意であり、例えば化粧水、乳液、クリーム、パック等のフェーシャル化粧料やファンデーション、口紅、アイシャドウ等のメーキャップ化粧料、芳香化粧料、浴用剤等に用いることができる。
The form of use is also arbitrary, and for example, it can be used for facial cosmetics such as lotions, emulsions, creams and packs, makeup cosmetics such as foundations, lipsticks and eye shadows, aromatic cosmetics, bath preparations and the like.
また、メーキャップ化粧品であれば、ファンデーション等、トイレタリー製品としてはボディーソープ、石けん等の形態に広く適用可能である。さらに、医薬部外品であれば、各種の軟膏剤等の形態に広く適用が可能である。そして、これらの剤型および形態に、本発明のヒアルロン酸産生促進剤の採り得る形態が限定されるものではない。
Also, makeup cosmetics can be widely applied to foundations and other toiletry products such as body soaps and soaps. Furthermore, if it is a quasi-drug, it can be widely applied to various ointment forms. And the form which can take the hyaluronic acid production promoter of this invention is not limited to these dosage forms and forms.
本発明のヒアルロン酸産生促進剤を飲食品や飼料等に配合する場合、植物体またはその抽出物の配合量（乾燥質量）は、それらの種類、目的、形態、利用方法などに応じて、適宜決めることができ、例えば、飲食品全量中に錠剤やカプセル剤等の場合は１～９０質量％が好ましく、その他の飲食品では０．００１～５０質量％が好ましい。成人一日当たり植物またはその抽出物の摂取量が約１～１，０００ｍｇ程度になるように調製することが好ましい。特に、保健用飲食品等として利用する場合には、本発明の有効成分を所定の効果が十分発揮されるような量で含有させることが好ましい。
When the hyaluronic acid production promoter of the present invention is blended in foods and drinks, feeds, etc., the blending amount (dry mass) of the plant body or its extract is appropriately determined according to the type, purpose, form, usage method, etc. For example, 1 to 90% by mass is preferable for tablets and capsules in the total amount of food and drink, and 0.001 to 50% by mass for other foods and drinks. It is preferable to prepare so that the daily intake of the plant or its extract per adult is about 1 to 1,000 mg. In particular, when used as a health food or drink, it is preferable to contain the active ingredient of the present invention in such an amount that a predetermined effect is sufficiently exhibited.
飲食品や飼料の形態としては、例えば、顆粒状、粒状、ペースト状、ゲル状、固形状、または、液体状に任意に成形することができる。これらには、飲食品等に含有することが認められている公知の各種物質、例えば、結合剤、崩壊剤、増粘剤、分散剤、再吸収促進剤、矯味剤、緩衝剤、界面活性剤、溶解補助剤、保存剤、乳化剤、等張化剤、安定化剤やｐＨ調製剤などの賦形剤を適宜含有させることができる。
As the form of food and drink or feed, for example, it can be arbitrarily shaped into granules, granules, pastes, gels, solids, or liquids. These include various known substances that are recognized to be contained in foods and drinks, such as binders, disintegrants, thickeners, dispersants, reabsorption accelerators, flavoring agents, buffers, and surfactants. Excipients such as solubilizers, preservatives, emulsifiers, tonicity agents, stabilizers and pH adjusters may be included as appropriate.
本発明のヒアルロン酸産生促進剤を医薬製剤として用いる場合、該製剤は経口的にあるいは非経口的（静脈投与、腹腔内投与、等）に適宜に使用される。剤型も任意で、例えば錠剤、顆粒剤、散剤、カプセル剤等の経口用固形製剤や、内服液剤、シロップ剤等の経口用液体製剤、または、注射剤などの非経口用液体製剤など、いずれの形態にも公知の方法により適宜調製することができる。これらの医薬製剤には、通常用いられる結合剤、崩壊剤、増粘剤、分散剤、再吸収促進剤、矯味剤、緩衝剤、界面活性剤、溶解補助剤、保存剤、乳化剤、等張化剤、安定化剤やｐＨ調整剤などの賦形剤を適宜使用してもよい。
When the hyaluronic acid production promoter of the present invention is used as a pharmaceutical preparation, the preparation is appropriately used orally or parenterally (intravenous administration, intraperitoneal administration, etc.). The dosage form is also arbitrary, for example, oral solid preparations such as tablets, granules, powders and capsules, oral liquid preparations such as internal liquids and syrups, and parenteral liquid preparations such as injections. These forms can also be appropriately prepared by known methods. For these pharmaceutical preparations, commonly used binders, disintegrants, thickeners, dispersants, reabsorption accelerators, corrigents, buffers, surfactants, solubilizers, preservatives, emulsifiers, isotonicity Excipients such as agents, stabilizers and pH adjusters may be used as appropriate.
本発明のヒアルロン酸産生促進剤を、皮膚外用剤、飲食品、医薬製剤等として用いる場合、優れたヒアルロン酸産生促進作用により、ヒト皮膚の老化防止、皮膚のはりや弾力保持、関節炎等の予防・治療、熱傷の初期の治療等に有効に用いられる。食品に添加した場合には、かかる食品を摂取することで、ヒアルロン酸産生促進効果を内から発揮することが期待される。
When the hyaluronic acid production promoter of the present invention is used as an external preparation for skin, foods and drinks, pharmaceutical preparations, etc., it has excellent hyaluronic acid production promoting action to prevent aging of human skin, retention of skin tension and elasticity, prevention of arthritis -Effectively used for treatment and early treatment of burns. When added to a food, it is expected that the hyaluronic acid production promoting effect will be exhibited from the inside by ingesting the food.
また上記症状や病態等の治療、予防、改善等の生理機能をコンセプトとして、その旨を表示した皮膚外用剤、機能性飲食品、特定保健用食品等に応用することができる。
In addition, it can be applied to skin external preparations, functional foods and drinks, foods for specified health use, etc. that indicate the physiological functions such as treatment, prevention, and improvement of the above symptoms and pathological conditions.
尚、本発明のヒアルロン酸産生促進剤の皮膚外用剤又は飲食品などへの添加の方法については、予め加えておいても、製造途中で添加しても良く、作業性を考えて適宜選択すれば良い。
The method for adding the hyaluronic acid production promoter of the present invention to an external preparation for skin or food and drink may be added in advance or during production, and may be appropriately selected in consideration of workability. It ’s fine.
本発明について以下に実施例を挙げてさらに詳述するが、本発明はこれによりなんら限定されるものではない。配合量は特記しない限り質量％で示す。
本実施例において、トゲドコロとしては、「トゲドコロ粉末」（タカラバイオ社製）のＤＭＳＯ（ジメチルスルホキシド）溶解物を用いた。まず、ヒアルロン酸産生促進効果に関する試験方法とその結果について説明する。 The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto. Unless otherwise specified, the amount is shown in mass%.
In this example, a DMSO (dimethyl sulfoxide) solution of “Tedokoro Powder” (manufactured by Takara Bio Inc.) was used as the toggedokoro. First, the test method regarding hyaluronic acid production promoting effect and the results will be described.
本実施例において、トゲドコロとしては、「トゲドコロ粉末」（タカラバイオ社製）のＤＭＳＯ（ジメチルスルホキシド）溶解物を用いた。まず、ヒアルロン酸産生促進効果に関する試験方法とその結果について説明する。 The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto. Unless otherwise specified, the amount is shown in mass%.
In this example, a DMSO (dimethyl sulfoxide) solution of “Tedokoro Powder” (manufactured by Takara Bio Inc.) was used as the toggedokoro. First, the test method regarding hyaluronic acid production promoting effect and the results will be described.
１．ヒアルロン酸産生促進効果試験方法
上記で得た試料のヒアルロン酸産生促進作用を評価した。すなわち、２４ウェルプレートに、５．０×１０4細胞／ウェルの濃度でヒト表皮角化細胞を播種し、コンフルエント状態にしたところで、各試料群（最終濃度１μｇ／ｍＬ、１０μｇ／ｍＬ）を含む５００μＬのEpiLife-KG2培養液を添加した。添加後、７２時間インキュベーションした後、ＥＬＩＳＡ法にてヒアルロン酸産生量を測定した。なお対照例（コントロール）としては、ＤＭＳＯ／ＰＢＳ溶液（試料添加なし）を用いた。
測定にはHyaluronan assay kit（生化学バイオビジネス社製）を用いた。測定値の単位はヒアルロナン（hyaluronan。ヒアルロン酸と同義）産生量（ｎｇ／ｍＬ）を示す。 1. Hyaluronic acid production promoting effect test method The hyaluronic acid production promoting action of the sample obtained above was evaluated. That is, when a human epidermal keratinocyte is seeded in a 24-well plate at a concentration of 5.0 × 10 4 cells / well and brought into a confluent state, each sample group (final concentration 1 μg / mL, 10 μg / mL) is included. 500 μL of EpiLife-KG2 culture medium was added. After the addition, after 72 hours of incubation, the amount of hyaluronic acid produced was measured by ELISA. A DMSO / PBS solution (no sample added) was used as a control example (control).
For the measurement, a Hyaluronan assay kit (manufactured by Seikagaku Biobusiness) was used. The unit of the measured value is hyaluronan (synonymous with hyaluronic acid) production (ng / mL).
上記で得た試料のヒアルロン酸産生促進作用を評価した。すなわち、２４ウェルプレートに、５．０×１０4細胞／ウェルの濃度でヒト表皮角化細胞を播種し、コンフルエント状態にしたところで、各試料群（最終濃度１μｇ／ｍＬ、１０μｇ／ｍＬ）を含む５００μＬのEpiLife-KG2培養液を添加した。添加後、７２時間インキュベーションした後、ＥＬＩＳＡ法にてヒアルロン酸産生量を測定した。なお対照例（コントロール）としては、ＤＭＳＯ／ＰＢＳ溶液（試料添加なし）を用いた。
測定にはHyaluronan assay kit（生化学バイオビジネス社製）を用いた。測定値の単位はヒアルロナン（hyaluronan。ヒアルロン酸と同義）産生量（ｎｇ／ｍＬ）を示す。 1. Hyaluronic acid production promoting effect test method The hyaluronic acid production promoting action of the sample obtained above was evaluated. That is, when a human epidermal keratinocyte is seeded in a 24-well plate at a concentration of 5.0 × 10 4 cells / well and brought into a confluent state, each sample group (
For the measurement, a Hyaluronan assay kit (manufactured by Seikagaku Biobusiness) was used. The unit of the measured value is hyaluronan (synonymous with hyaluronic acid) production (ng / mL).
2．結果
トゲドコロ含有培地で培養した細胞でのヒアルロン酸量が、対照群と比較して大幅に増加した。すなわちトゲドコロに極めて優れたヒアルロン酸産生促進効果があることが確認された。その結果を図１に示した。 2． Results The amount of hyaluronic acid in the cells cultured in the medium containing Togedokoro was significantly increased compared to the control group. That is, it was confirmed that Tedokoro has an extremely excellent hyaluronic acid production promoting effect. The results are shown in FIG.
トゲドコロ含有培地で培養した細胞でのヒアルロン酸量が、対照群と比較して大幅に増加した。すなわちトゲドコロに極めて優れたヒアルロン酸産生促進効果があることが確認された。その結果を図１に示した。 2． Results The amount of hyaluronic acid in the cells cultured in the medium containing Togedokoro was significantly increased compared to the control group. That is, it was confirmed that Tedokoro has an extremely excellent hyaluronic acid production promoting effect. The results are shown in FIG.
図１から分かるように、本発明の植物は、優れたヒアルロン酸産生促進効果を有しており、ヒアルロン酸産生促進剤として有用である。
このため本発明のヒアルロン酸産生促進剤を配合することで、ヒアルロン酸産生促進効果を有する皮膚外用剤、経口用組成物（例えば機能剤、飲食品など）、医薬製剤等を提供することができ、種々の症状や疾病、病態等の予防、防止、改善、治療等に役立つ。
具体的適用例としては、皮膚のたるみ・しわ、ハリ・弾力の低下などの皮膚老化を予防、改善、治療したり、関節炎等の予防・治療、熱傷の初期の治療等が挙げられる。ただしこれら例示に適用が限定されるものでない。 As can be seen from FIG. 1, the plant of the present invention has an excellent hyaluronic acid production promoting effect, and is useful as a hyaluronic acid production promoter.
Therefore, by incorporating the hyaluronic acid production promoter of the present invention, it is possible to provide an external preparation for skin having an effect of promoting hyaluronic acid production, an oral composition (for example, a functional agent, food and drink), a pharmaceutical preparation and the like. It is useful for prevention, prevention, improvement, treatment, etc. of various symptoms, diseases, and pathological conditions.
Specific examples of application include prevention, improvement and treatment of skin aging such as sagging / wrinkling of skin, reduction of elasticity and elasticity, prevention / treatment of arthritis, and early treatment of burns. However, application is not limited to these examples.
このため本発明のヒアルロン酸産生促進剤を配合することで、ヒアルロン酸産生促進効果を有する皮膚外用剤、経口用組成物（例えば機能剤、飲食品など）、医薬製剤等を提供することができ、種々の症状や疾病、病態等の予防、防止、改善、治療等に役立つ。
具体的適用例としては、皮膚のたるみ・しわ、ハリ・弾力の低下などの皮膚老化を予防、改善、治療したり、関節炎等の予防・治療、熱傷の初期の治療等が挙げられる。ただしこれら例示に適用が限定されるものでない。 As can be seen from FIG. 1, the plant of the present invention has an excellent hyaluronic acid production promoting effect, and is useful as a hyaluronic acid production promoter.
Therefore, by incorporating the hyaluronic acid production promoter of the present invention, it is possible to provide an external preparation for skin having an effect of promoting hyaluronic acid production, an oral composition (for example, a functional agent, food and drink), a pharmaceutical preparation and the like. It is useful for prevention, prevention, improvement, treatment, etc. of various symptoms, diseases, and pathological conditions.
Specific examples of application include prevention, improvement and treatment of skin aging such as sagging / wrinkling of skin, reduction of elasticity and elasticity, prevention / treatment of arthritis, and early treatment of burns. However, application is not limited to these examples.
以下に、種々の剤型の本発明によるヒアルロン酸産生促進剤の配合例を処方例として説明する。本発明はこの処方例によって何ら限定されるものではなく、特許請求の範囲によって特定されるものであることはいうまでもない。以下の処方例において、ヒアルロン酸産生促進剤としては、タカラバイオ社製の「トゲドコロ粉末」を用いた。
Hereinafter, formulation examples of hyaluronic acid production promoters according to the present invention in various dosage forms will be described as formulation examples. Needless to say, the present invention is not limited by these formulation examples and is specified by the scope of claims. In the following formulation examples, “Tagedokoro powder” manufactured by Takara Bio Inc. was used as the hyaluronic acid production promoter.
［配合処方例１：キャンディー］
砂糖 １８００ｍｇ
水飴 １９２６ｍｇ
ヒアルロン酸産生促進剤： トゲドコロ粉末（乾燥質量） ２００ｍｇ
コラーゲンペプチド ３０ｍｇ
ハトムギ抽出物（乾燥質量） ２ｍｇ
ハス胚芽抽出物（乾燥質量） ２ｍｇ
香料 ４０ｍｇ
（合計） ４０００ｍｇ [Formulation Example 1: Candy]
1800mg sugar
Minamata 1926mg
Hyaluronic acid production promoter: Togedokoro powder (dry mass) 200mg
Collagen peptide 30mg
Pearl barley extract (dry mass) 2mg
Lotus germ extract (dry mass) 2mg
Fragrance 40mg
(Total) 4000mg
砂糖 １８００ｍｇ
水飴 １９２６ｍｇ
ヒアルロン酸産生促進剤： トゲドコロ粉末（乾燥質量） ２００ｍｇ
コラーゲンペプチド ３０ｍｇ
ハトムギ抽出物（乾燥質量） ２ｍｇ
ハス胚芽抽出物（乾燥質量） ２ｍｇ
香料 ４０ｍｇ
（合計） ４０００ｍｇ [Formulation Example 1: Candy]
1800mg sugar
Minamata 1926mg
Hyaluronic acid production promoter: Togedokoro powder (dry mass) 200mg
Collagen peptide 30mg
Pearl barley extract (dry mass) 2mg
Lotus germ extract (dry mass) 2mg
Fragrance 40mg
(Total) 4000mg
［配合処方例２：錠剤］
ショ糖エステル ７０ｍｇ
結晶セルロース ７４ｍｇ
メチルセルロース ３６ｍｇ
グリセリン ２５ｍｇ
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） １２０ｍｇ
コラーゲンペプチド ６０ｍｇ
ハトムギ抽出物（乾燥質量） １０ｍｇ
Ｎ－アセチルグルコサミン １８０ｍｇ
ヒアルロン酸 １５０ｍｇ
ビタミンＥ ３０ｍｇ
ビタミンＢ６ ２０ｍｇ
ビタミンＢ２ １０ｍｇ
α－リポ酸 ２０ｍｇ
コエンザイムＱ１０ ４０ｍｇ
セラミド（コンニャク抽出物） ５５ｍｇ
Ｌ－プロリン ３００ｍｇ
（合計） １２００ｍｇ [Formulation Example 2: Tablet]
Sucrose ester 70mg
Crystalline cellulose 74mg
Methylcellulose 36mg
Glycerin 25mg
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 120mg
Collagen peptide 60mg
Pearl barley extract (dry mass) 10mg
N-acetylglucosamine 180mg
Hyaluronic acid 150mg
Vitamin E 30mg
Vitamin B6 20mg
Vitamin B2 10mg
α-Lipoic acid 20mg
Coenzyme Q10 40mg
Ceramide (konjac extract) 55mg
L-proline 300mg
(Total) 1200mg
ショ糖エステル ７０ｍｇ
結晶セルロース ７４ｍｇ
メチルセルロース ３６ｍｇ
グリセリン ２５ｍｇ
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） １２０ｍｇ
コラーゲンペプチド ６０ｍｇ
ハトムギ抽出物（乾燥質量） １０ｍｇ
Ｎ－アセチルグルコサミン １８０ｍｇ
ヒアルロン酸 １５０ｍｇ
ビタミンＥ ３０ｍｇ
ビタミンＢ６ ２０ｍｇ
ビタミンＢ２ １０ｍｇ
α－リポ酸 ２０ｍｇ
コエンザイムＱ１０ ４０ｍｇ
セラミド（コンニャク抽出物） ５５ｍｇ
Ｌ－プロリン ３００ｍｇ
（合計） １２００ｍｇ [Formulation Example 2: Tablet]
Sucrose ester 70mg
Crystalline cellulose 74mg
Methylcellulose 36mg
Glycerin 25mg
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 120mg
Collagen peptide 60mg
Pearl barley extract (dry mass) 10mg
N-acetylglucosamine 180mg
Hyaluronic acid 150mg
Vitamin E 30mg
Vitamin B6 20mg
Vitamin B2 10mg
α-Lipoic acid 20mg
Coenzyme Q10 40mg
Ceramide (konjac extract) 55mg
L-proline 300mg
(Total) 1200mg
［配合処方例３：ソフトカプセル］
食用大豆油 ５２８ｍｇ
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） ９０ｍｇ
コラーゲンペプチド ４５ｍｇ
ハトムギ抽出物（乾燥質量） ８ｍｇ
ハス胚芽抽出物（乾燥質量） １６ｍｇ
ローヤルゼリー ７０ｍｇ
マカ ６０ｍｇ
ＧＡＢＡ（＝γ－アミノ酪酸） ３０ｍｇ
ミツロウ ６０ｍｇ
ゼラチン ３７５ｍｇ
グリセリン １１３ｍｇ
グリセリン脂肪酸エステル １０５ｍｇ
（合計）１５００ｍｇ [Formulation formulation example 3: soft capsule]
Edible soybean oil 528mg
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 90mg
Collagen peptide 45mg
Pearl barley extract (dry mass) 8mg
Lotus germ extract (dry mass) 16mg
Royal Jelly 70mg
Maca 60mg
GABA (= γ-aminobutyric acid) 30mg
Beeswax 60mg
Gelatin 375mg
Glycerin 113mg
Glycerin fatty acid ester 105mg
(Total) 1500mg
食用大豆油 ５２８ｍｇ
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） ９０ｍｇ
コラーゲンペプチド ４５ｍｇ
ハトムギ抽出物（乾燥質量） ８ｍｇ
ハス胚芽抽出物（乾燥質量） １６ｍｇ
ローヤルゼリー ７０ｍｇ
マカ ６０ｍｇ
ＧＡＢＡ（＝γ－アミノ酪酸） ３０ｍｇ
ミツロウ ６０ｍｇ
ゼラチン ３７５ｍｇ
グリセリン １１３ｍｇ
グリセリン脂肪酸エステル １０５ｍｇ
（合計）１５００ｍｇ [Formulation formulation example 3: soft capsule]
Edible soybean oil 528mg
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 90mg
Collagen peptide 45mg
Pearl barley extract (dry mass) 8mg
Lotus germ extract (dry mass) 16mg
Royal Jelly 70mg
Maca 60mg
GABA (= γ-aminobutyric acid) 30mg
Beeswax 60mg
Gelatin 375mg
Glycerin 113mg
Glycerin fatty acid ester 105mg
(Total) 1500mg
［配合処方例４：ソフトカプセル］
玄米胚芽油 ６５０ｍｇ
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） ３００ｍｇ
コラーゲンペプチド ２５５ｍｇ
ハトムギ抽出物（乾燥質量） ５０ｍｇ
レスベラトロール ５ｍｇ
エラスチン １８０ｍｇ
ＤＮＡ ３０ｍｇ
葉酸 ３０ｍｇ
（合計）１５００ｍｇ [Formulation formulation example 4: soft capsule]
Brown rice germ oil 650mg
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 300mg
Collagen peptide 255mg
Pearl barley extract (dry mass) 50mg
Resveratrol 5mg
Elastin 180mg
DNA 30mg
Folic acid 30mg
(Total) 1500mg
玄米胚芽油 ６５０ｍｇ
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） ３００ｍｇ
コラーゲンペプチド ２５５ｍｇ
ハトムギ抽出物（乾燥質量） ５０ｍｇ
レスベラトロール ５ｍｇ
エラスチン １８０ｍｇ
ＤＮＡ ３０ｍｇ
葉酸 ３０ｍｇ
（合計）１５００ｍｇ [Formulation formulation example 4: soft capsule]
Brown rice germ oil 650mg
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 300mg
Collagen peptide 255mg
Pearl barley extract (dry mass) 50mg
Resveratrol 5mg
Elastin 180mg
DNA 30mg
Folic acid 30mg
(Total) 1500mg
［配合処方例５：顆粒］
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） １４０ｍｇ
コラーゲンペプチド ７０ｍｇ
ハトムギ抽出物（乾燥質量） ２０ｍｇ
ハス胚芽抽出物（乾燥質量） ４０ｍｇ
ビタミンＣ １５０ｍｇ
大豆イソフラボン ２７０ｍｇ
還元乳糖 ３６０ｍｇ
大豆オリゴ糖 ３６ｍｇ
エリスリトール ３６ｍｇ
デキストリン ３０ｍｇ
香料 ２４ｍｇ
クエン酸 ２４ｍｇ
（合計） １２００ｍｇ [Formulation Example 5: Granules]
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 140mg
Collagen peptide 70mg
Pearl barley extract (dry mass) 20mg
Lotus germ extract (dry mass) 40mg
Vitamin C 150mg
Soy isoflavone 270mg
Reduced lactose 360mg
Soybean oligosaccharide 36mg
Erythritol 36mg
Dextrin 30mg
Fragrance 24mg
Citric acid 24mg
(Total) 1200mg
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） １４０ｍｇ
コラーゲンペプチド ７０ｍｇ
ハトムギ抽出物（乾燥質量） ２０ｍｇ
ハス胚芽抽出物（乾燥質量） ４０ｍｇ
ビタミンＣ １５０ｍｇ
大豆イソフラボン ２７０ｍｇ
還元乳糖 ３６０ｍｇ
大豆オリゴ糖 ３６ｍｇ
エリスリトール ３６ｍｇ
デキストリン ３０ｍｇ
香料 ２４ｍｇ
クエン酸 ２４ｍｇ
（合計） １２００ｍｇ [Formulation Example 5: Granules]
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 140mg
Collagen peptide 70mg
Pearl barley extract (dry mass) 20mg
Lotus germ extract (dry mass) 40mg
Vitamin C 150mg
Soy isoflavone 270mg
Reduced lactose 360mg
Soybean oligosaccharide 36mg
Erythritol 36mg
Dextrin 30mg
Fragrance 24mg
Citric acid 24mg
(Total) 1200mg
［配合処方例６：ドリンク剤（５０ｍＬ中）］
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） １００ｍｇ
コラーゲンペプチド ５ｍｇ
ハトムギ抽出物（乾燥質量） ２ｍｇ
還元麦芽糖水飴 ２８ｍｇ
エリスリトール ８ｍｇ
クエン酸 ２ｍｇ
香料 １．３ｍｇ
Ｎ－アセチルグルコサミン １ｍｇ
ヒアルロン酸 ０．５ｍｇ
ビタミンＥ ０．３ｍｇ
α－リポ酸 ０．２ｍｇ
コエンザイムＱ１０ １．２ｍｇ
セラミド（コンニャク抽出物） ０．４ｍｇ
Ｌ－プロリン ２ｍｇ
水 残余 [Composition Example 6: Drink (in 50 mL)]
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 100mg
Collagen peptide 5mg
Pearl barley extract (dry mass) 2mg
Reduced maltose starch syrup 28mg
Erythritol 8mg
Citric acid 2mg
Fragrance 1.3mg
N-acetylglucosamine 1mg
Hyaluronic acid 0.5mg
Vitamin E 0.3mg
α-Lipoic acid 0.2mg
Coenzyme Q10 1.2mg
Ceramide (konjac extract) 0.4mg
L-proline 2mg
Water residue
ヒアルロン酸産生促進剤：トゲドコロ粉末（乾燥質量） １００ｍｇ
コラーゲンペプチド ５ｍｇ
ハトムギ抽出物（乾燥質量） ２ｍｇ
還元麦芽糖水飴 ２８ｍｇ
エリスリトール ８ｍｇ
クエン酸 ２ｍｇ
香料 １．３ｍｇ
Ｎ－アセチルグルコサミン １ｍｇ
ヒアルロン酸 ０．５ｍｇ
ビタミンＥ ０．３ｍｇ
α－リポ酸 ０．２ｍｇ
コエンザイムＱ１０ １．２ｍｇ
セラミド（コンニャク抽出物） ０．４ｍｇ
Ｌ－プロリン ２ｍｇ
水 残余 [Composition Example 6: Drink (in 50 mL)]
Hyaluronic acid production promoter: Tedokoro powder (dry mass) 100mg
Collagen peptide 5mg
Pearl barley extract (dry mass) 2mg
Reduced maltose starch syrup 28mg
Erythritol 8mg
Citric acid 2mg
Fragrance 1.3mg
N-acetylglucosamine 1mg
Hyaluronic acid 0.5mg
Vitamin E 0.3mg
α-Lipoic acid 0.2mg
Coenzyme Q10 1.2mg
Ceramide (konjac extract) 0.4mg
L-proline 2mg
Water residue
Claims (3)
- トゲドコロの植物体又はその抽出物を含むことを特徴とする、ヒアルロン酸産生促進剤。 Hyaluronic acid production promoter characterized by comprising a plant of Togekokoro or an extract thereof.
- 前記植物体はトゲドコロの植物体の乾燥粉末であることを特徴とする、請求項１に記載のヒアルロン酸産生促進剤。 The hyaluronic acid production promoter according to claim 1, wherein the plant body is a dry powder of a plant of Tedokoro.
- 前記植物体はトゲドコロの植物体の塊茎であることを特徴とする、請求項１又は２に記載のヒアルロン酸産生促進剤。
The hyaluronic acid production promoter according to claim 1 or 2, wherein the plant body is a tuber of a plant of Tedokoro.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW100128645A TW201210633A (en) | 2010-09-13 | 2011-08-11 | Agent for promoting hyaluronic acid production |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010204407A JP2012056919A (en) | 2010-09-13 | 2010-09-13 | Hyaluronic acid production promotor |
| JP2010-204407 | 2010-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012035904A1 true WO2012035904A1 (en) | 2012-03-22 |
Family
ID=45831378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2011/067829 WO2012035904A1 (en) | 2010-09-13 | 2011-08-04 | Agent for promoting hyaluronic acid production |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2012056919A (en) |
| TW (1) | TW201210633A (en) |
| WO (1) | WO2012035904A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014126486A1 (en) | 2013-02-15 | 2014-08-21 | Leano Milagros B | Pharmacological indications and uses of preparations from dioscorea hispida |
| WO2014041528A3 (en) * | 2012-09-14 | 2014-12-18 | Martin Roslain Margaret | A composition for the treatment of cutaneous signs of ageing |
| EP3319454A4 (en) * | 2015-07-09 | 2019-03-06 | Nofar, Gil | Espresso beverage formulation comprising collagen peptides |
| CN114404533A (en) * | 2022-03-31 | 2022-04-29 | 江西纤仁本草堂生物科技有限公司 | Medicine for treating burn and scald and its preparing process |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012147842A1 (en) * | 2011-04-28 | 2012-11-01 | ビーエイチエヌ株式会社 | Beautiful-skin-promoting agent and use thereof |
| RU2527344C2 (en) * | 2012-09-03 | 2014-08-27 | Закрытое акционерное общество "Эвалар" | Composition for internal use for hormone skin aging correction |
| JP6330119B2 (en) * | 2016-04-27 | 2018-05-30 | 株式会社東洋新薬 | Beauty composition |
| JP6218915B1 (en) * | 2016-12-26 | 2017-10-25 | 株式会社東洋新薬 | Beauty composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007274985A (en) * | 2006-04-07 | 2007-10-25 | Takara Bio Inc | Food containing treated product derived from dioscorea esculenta |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003312344A (en) * | 2002-04-24 | 2003-11-06 | Nissan Motor Co Ltd | Seat belt guide structure |
| JP2008094734A (en) * | 2006-10-10 | 2008-04-24 | Shiseido Co Ltd | Antiwrinkle agent and external preparation for skin |
-
2010
- 2010-09-13 JP JP2010204407A patent/JP2012056919A/en active Pending
-
2011
- 2011-08-04 WO PCT/JP2011/067829 patent/WO2012035904A1/en active Application Filing
- 2011-08-11 TW TW100128645A patent/TW201210633A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007274985A (en) * | 2006-04-07 | 2007-10-25 | Takara Bio Inc | Food containing treated product derived from dioscorea esculenta |
Non-Patent Citations (3)
| Title |
|---|
| ARTHRITIS RES. THER., vol. 6, no. 4, 2004, pages R373 - R383 * |
| J. BIOL. CHEM., vol. 285, no. 1, January 2010 (2010-01-01), pages 409 - 421 * |
| STEROIDS, vol. 74, 2009, pages 504 - 511 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014041528A3 (en) * | 2012-09-14 | 2014-12-18 | Martin Roslain Margaret | A composition for the treatment of cutaneous signs of ageing |
| WO2014126486A1 (en) | 2013-02-15 | 2014-08-21 | Leano Milagros B | Pharmacological indications and uses of preparations from dioscorea hispida |
| EP3319454A4 (en) * | 2015-07-09 | 2019-03-06 | Nofar, Gil | Espresso beverage formulation comprising collagen peptides |
| CN114404533A (en) * | 2022-03-31 | 2022-04-29 | 江西纤仁本草堂生物科技有限公司 | Medicine for treating burn and scald and its preparing process |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012056919A (en) | 2012-03-22 |
| TW201210633A (en) | 2012-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101841256B1 (en) | Composition for improving skin wrinkle and enhancing elasticity | |
| WO2012035904A1 (en) | Agent for promoting hyaluronic acid production | |
| KR102100270B1 (en) | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening | |
| KR101776071B1 (en) | Composition containing red sword bean extract for anti-aging and whitening | |
| JP2011195504A (en) | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent | |
| JP2011195503A (en) | Protein glycation inhibitor | |
| WO2011115061A1 (en) | Hyaluronic acid production promoter | |
| JP4420357B1 (en) | Hyaluronic acid production promoter | |
| JP2011195531A (en) | Protein glycation inhibitor | |
| JP2010229111A (en) | Hyaluronic acid production promoter | |
| JP2011195502A (en) | Fibroblast proliferation promoter, anti-ageing agent and wrinkle-ameliorating agent | |
| JP2011195532A (en) | Protein glycation inhibitor | |
| JP2011195534A (en) | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent | |
| KR20150019680A (en) | Composition for skin cell regeneration, anti-wrinkle and antioxidant | |
| JP2011195530A (en) | Protein glycation inhibitor | |
| JP4413272B1 (en) | Hyaluronic acid production promoter | |
| KR20150019577A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR102014961B1 (en) | Composition for anti oxidation containing extract of soybean pod | |
| JP2011195505A (en) | Type-i collagen production promoter, anti-aging agent and wrinkle-ameliorating agent | |
| KR102000516B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR101988988B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening | |
| KR102014960B1 (en) | Composition for anti oxidation containing extract of soybean root | |
| KR101989009B1 (en) | Composition for skin cell regeneration, anti-wrinkle and antioxidant | |
| KR101978182B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, and anti-imflamation | |
| KR101978665B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11824912 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11824912 Country of ref document: EP Kind code of ref document: A1 |